- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01011556
A Study for the Transdermal Application of Teriparatide
September 21, 2012 updated by: Eli Lilly and Company
A Phase 2 Study for Transdermal Application of Teriparatide
The primary purpose of this study is to help answer the following research questions:
- How teriparatide given using a skin patch (transferred through the skin using the ViaDerm Teriparatide System) compares to teriparatide injected under the skin with a needle (pen injector) affects your bone density (how solid or porous your bones are).
- The safety of the teriparatide skin patch and any side effects that might be associated with it.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Teriparatide 20 micrograms (mcg) per day is currently only available as a subcutaneous (SQ) injection and many patients with severe osteoporosis for whom anabolic therapy with teriparatide is appropriate are either unwilling or physically unable to self-inject.
The purpose of this Phase 2 study is to identify a transdermal dose or doses that will be comparable to the teriparatide 20 mcg SQ dose from a pharmacodynamic (PD) and safety standpoint for use in future Phase 3 studies.
Study Type
Interventional
Enrollment (Actual)
233
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina, C1128AAF
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Parnu, Estonia, 80010
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tallin, Estonia, 10138
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tartu, Estonia, 50410
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Balatonfured, Hungary, 8230
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Budapest, Hungary, 1036
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Debrecen, Hungary, 4043
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Esztergom, Hungary, 2500
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Gyor, Hungary, 9023
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Szombathely, Hungary, H-9700
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tatabanya, Hungary, 2800
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Guadalajara, Mexico, 44158
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Mexico City, Mexico, 03300
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Monterrey, Mexico, 64460
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Bucharest, Romania, 011025
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Cluj-Napoca, Romania, 400006
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Lasi, Romania, 700111
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Timisoara, Romania, 300736
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Ambulatory, postmenopausal women.
- Centrally confirmed lumbar spine or femoral neck bone mineral density (BMD) T-score of less than or equal to -2.5.
- Without language barrier, cooperative, expected to return for all follow-up procedures, and have given informed consent after being informed of the risks, medications, and procedures to be used in the study.
- Able to use the pen-type injection delivery system and the ViaDerm Teriparatide System satisfactorily in the opinion of the investigator, or with the help of a family member or caregiver.
- Able to be reached by telephone for follow-up contact between visits
Exclusion Criteria:
- Abnormal laboratory values for albumin and alkaline phosphatase.
- Laboratory values outside the ranges defined in the protocol for the following: Serum calcium, intact parathyroid hormone (iPTH), 25 hydroxyvitamin D, and 24-hour urine calcium
- History of diseases other than postmenopausal osteoporosis that affect bone metabolism, such as Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hypoparathyroidism, hyperparathyroidism, and intestinal malabsorption.
- History of malignant neoplasms in the 5 years prior to randomization, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix treated definitively more than 1 year prior to entry into the study may be randomized.
- Use of a pacemaker.
- Known chronic dermatological disorder, such as contact dermatitis
- History of allergy or sensitivity to tapes or adhesives
- Patients prone to bleeding with coagulopathies, such as hemophilia or thrombocytopenia.
- Patients who have an increased baseline risk of osteosarcoma, Paget's disease of the bone, or unexplained elevations of alkaline phosphatase; or prior external beam, implant radiation therapy involving the skeleton, or previous primary skeletal malignancy.
- Major fracture within the past year in the femur, tibia, humerus, or radius (with or without ulna).
Treatment with:
- calcitonins in the 2 months prior to randomization.
- oral, transdermal/patch, or injectable estrogens, progestins, estrogen analogs, estrogen agonists, estrogen antagonists, selective estrogen receptor modulators, or tibolone in the 3 months prior to randomization; treatment with intravaginal estrogens in doses higher than 0.3 mg of conjugated equine estrogen, or the equivalent, for more than 3 doses per week in the 3 months prior to randomization.
- androgens or other anabolic steroids in the 6 months prior to randomization.
- fluorides in the 2 years prior to randomization. (Previous or current use of fluoridated water or topical dental fluoride treatments are permitted.)
- oral bisphosphonates for more than 2 consecutive months in the 6 months prior to randomization; treatment with intravenous bisphosphonates in the 6 months prior to randomization; treatment with more than 1 cycle of intermittent oral bisphosphonates in the 6 months prior to randomization; or having received the last cycle of this intermittent oral regimen less than 4 weeks prior to screening.
- patients receiving intravenous zoledronic acid during the 12 months prior to randomization.
- vitamin D greater than 50,000 International Units (IU) per week or with any dose of calcitriol or vitamin D analogs or agonists in the 6 months prior to randomization.
- systemic corticosteroids in the 1 month prior to randomization or for more than 30 days in the 1 year prior to randomization. (Ophthalmic, otic, topical, orally inhaled, nasally inhaled, or intra-articular corticosteroid therapy may be used without these restrictions.)
- any other drug known to significantly affect bone metabolism in the 6 months prior to randomization.
- warfarin or other coumadin anticoagulants in the 1 month prior to randomization.
- any investigational drug in the 1 month prior to entry into the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 20 mcg Subcutaneous Teriparatide
Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.
|
Administered subcutaneously once daily for 12 months
Other Names:
|
Experimental: 30 mcg Transdermal Teriparatide
Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily.
Participants were blinded to dose level.
|
Administered transdermally, applied once daily for 6 hours over 12 months
Other Names:
|
Experimental: 50 mcg Transdermal Teriparatide
Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily.
Participants were blinded to dose level.
|
Administered transdermally, applied once daily for 6 hours over 12 months
Other Names:
|
Experimental: 80 mcg Transdermal Teriparatide
Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily.
Participants were blinded to dose level.
|
Administered transdermally, applied once daily for 6 hours over 12 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months
Time Frame: Baseline, 12 Months
|
Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA).
BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar).
Analyses were performed using ANCOVA model and least square (LS) means were adjusted for baseline BMD values as a covariate and pooled site and treatment as fixed effects.
|
Baseline, 12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 6 Months
Time Frame: Baseline, 6 Months
|
Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA).
BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar).
Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.
|
Baseline, 6 Months
|
Time Course Change of BMD Response at the Lumbar Spine
Time Frame: Baseline to 6 Months and 12 Months
|
To assess the time course of the treatment, the BMD data of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA) and analyzed using a mixed model repeated measures (MMRM) method, with the repeated measure occurring at each visit (for example, 6 and 12 month).
BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar).
|
Baseline to 6 Months and 12 Months
|
Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP)
Time Frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months
|
Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.
|
Baseline, 1 Month, 3 Months, 6 Months, 12 Months
|
Percent Change From Baseline of C-Terminal Telopeptide (CTX)
Time Frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months
|
C-terminal telopeptide is a marker of bone resorption.
|
Baseline, 1 Month, 3 Months, 6 Months, 12 Months
|
Percent Change From Baseline in Serum Procollagen Type 1 C-Propeptide (P1CP) at 1 Month
Time Frame: Baseline, 1 Month
|
Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.
|
Baseline, 1 Month
|
Convenience/Ease of Use Questionnaire (CEUQ)
Time Frame: baseline up to 12 months
|
CEUQ consists of 5 sections and 16 questions using a 5-point Likert scale designed to collect measures for ease of use (S1), convenience of use (S2), confidence of use (S3), fear of use (S4), and overall satisfaction with therapy (S5).
CEUQ is not a validated instrument.
|
baseline up to 12 months
|
Change in Serum Calcium With and Without Adjustments for Serum Albumin From Predose to After 4 and 6 Hours
Time Frame: Baseline, 12 Months
|
Serum calcium adjusted for serum albumin levels is calculated using the following formula: Total Calcium + [(40 - albumin) x 0.02].
Analysis for serum calcium and albumin adjusted serum calcium were collected at predose, 4 hours (h) post-dose (PD) and 6 h PD at baseline and 12 months (mon).
|
Baseline, 12 Months
|
Change From Baseline in Urine Calcium Excretion at 6 and 12 Months
Time Frame: Baseline, 6 Months, 12 Months
|
Baseline, 6 Months, 12 Months
|
|
Change From Pre-dose and Postdose Supine and Standing SBP and DBP at Baseline (BL) and 12 Months (Mon)
Time Frame: Pre-Dose, 30 minutes, 2 hours Post-Dose at Baseline and 12 Months
|
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) measured at pre-dose and 30 minutes (min) and 2 hours (hr) post-dose in both the supine and standing position.
|
Pre-Dose, 30 minutes, 2 hours Post-Dose at Baseline and 12 Months
|
Change From Pre-dose to Postdose in Supine and Standing Heart Rate at Baseline (BL) and 12 Months (Mon).
Time Frame: Pre-dose, 30 minutes, 2 hours at Baseline and 12 Months
|
Pre-dose, 30 minutes, 2 hours at Baseline and 12 Months
|
|
Number of Participants With Parathyroid Hormone (PTH) Specific Antibody Levels
Time Frame: Baseline and 1, 3, 12, and 13 Months (mon)
|
Participants were tested for anti-recombinant teriparatide and anti-synthetic teriparatide titers.
Either none were detected (ND) or antibodies were determined to be present if the teriparatide specific antibody titers were at least 1:8 (titer 1:8).
|
Baseline and 1, 3, 12, and 13 Months (mon)
|
Pharmacokinetics Parameters: Area Under the Curve (AUC)
Time Frame: Baseline, 1 Month, 3 Months, and 12 Months
|
Due to high intra-subject variability, data was not analyzed for this outcome measure.
|
Baseline, 1 Month, 3 Months, and 12 Months
|
Pharmacokinetics Parameters: Maximal Concentration (Cmax)
Time Frame: Baseline, 1 Month, 3 Months, 12 Months
|
Due to high intra-subject variability, data was not analyzed for this outcome measure.
|
Baseline, 1 Month, 3 Months, 12 Months
|
DRAIZE Edema Assessment at Baseline Through 13 Month Follow-up
Time Frame: 13 Month follow-up
|
Severity of edema was categorized based on a 5 point scale: 0=no edema, 4=severe edema (defined as an area raised more than 1 millimeter and extending beyond area of exposure)
|
13 Month follow-up
|
DRAIZE Erythema Assessment at Baseline Through 13 Month Follow-up
Time Frame: 13 Month follow-up
|
Severity of erythema was categorized based on a 5 point scale: 0=no erythema, 4=severe erythema (defined as beet red to eschar)
|
13 Month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
November 9, 2009
First Submitted That Met QC Criteria
November 9, 2009
First Posted (Estimate)
November 11, 2009
Study Record Updates
Last Update Posted (Estimate)
October 23, 2012
Last Update Submitted That Met QC Criteria
September 21, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12641
- I2Y-MC-GHFA(c) (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on Subcutaneous Teriparatide
-
University of CalgaryNot yet recruiting
-
Eli Lilly and CompanyCompletedOsteoporosis, Post-MenopausalChina
-
Eli Lilly and CompanyCompletedOsteoporosis, PostmenopausalKorea, Republic of
-
Eli Lilly and CompanyCompleted
-
Massachusetts General HospitalCompletedPostmenopausal OsteoporosisUnited States
-
Medical University of ViennaSt. Vincent Hospital, ViennaCompletedDiabetes Type 2 | Postmenopausal OsteoporosisAustria
-
Pfenex, IncCompleted
-
Beijing Friendship HospitalUnknown
-
Eli Lilly and CompanyCompleted
-
University of California, San FranciscoNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed